Concepts are derived automatically from a person's publications.
 
																	
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
    
| Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
| Clinical Decision-Making | 3 | 2024 | 320 | 1.230 | Why? | 
| Infection Control | 1 | 2025 | 158 | 0.860 | Why? | 
| Air Pollution, Indoor | 1 | 2025 | 177 | 0.810 | Why? | 
| Diagnostic Tests, Routine | 2 | 2020 | 109 | 0.750 | Why? | 
| Internal Medicine | 1 | 2024 | 253 | 0.740 | Why? | 
| Respiratory Tract Infections | 1 | 2025 | 395 | 0.700 | Why? | 
| Mitral Valve Stenosis | 1 | 2019 | 18 | 0.620 | Why? | 
| Probability | 1 | 2020 | 311 | 0.620 | Why? | 
| Likelihood Functions | 1 | 2019 | 143 | 0.610 | Why? | 
| Endocarditis, Bacterial | 1 | 2019 | 43 | 0.600 | Why? | 
| Echocardiography, Doppler | 1 | 2019 | 109 | 0.590 | Why? | 
| Research Design | 1 | 2024 | 1108 | 0.580 | Why? | 
| Data Interpretation, Statistical | 1 | 2020 | 352 | 0.580 | Why? | 
| Research Personnel | 1 | 2020 | 168 | 0.580 | Why? | 
| Dabigatran | 1 | 2018 | 21 | 0.580 | Why? | 
| Guidelines as Topic | 1 | 2020 | 277 | 0.570 | Why? | 
| ROC Curve | 1 | 2019 | 543 | 0.550 | Why? | 
| Point-of-Care Systems | 1 | 2019 | 163 | 0.540 | Why? | 
| Biomedical Research | 1 | 2020 | 688 | 0.420 | Why? | 
| Stroke | 2 | 2019 | 1122 | 0.410 | Why? | 
| Atrial Fibrillation | 1 | 2018 | 390 | 0.410 | Why? | 
| Anti-Bacterial Agents | 2 | 2019 | 1790 | 0.380 | Why? | 
| Internship and Residency | 1 | 2022 | 1131 | 0.380 | Why? | 
| Hospitalists | 2 | 2024 | 243 | 0.320 | Why? | 
| Heart Failure | 2 | 2020 | 2210 | 0.320 | Why? | 
| Patient Safety | 2 | 2024 | 305 | 0.310 | Why? | 
| Bayes Theorem | 2 | 2022 | 405 | 0.310 | Why? | 
| Aortic Valve Insufficiency | 2 | 2016 | 47 | 0.250 | Why? | 
| Air Microbiology | 1 | 2025 | 46 | 0.230 | Why? | 
| Clinical Competence | 2 | 2024 | 1086 | 0.230 | Why? | 
| Humans | 22 | 2025 | 136899 | 0.220 | Why? | 
| Academic Medical Centers | 2 | 2024 | 494 | 0.220 | Why? | 
| Psychological Tests | 1 | 2024 | 139 | 0.200 | Why? | 
| Aortic Valve | 2 | 2016 | 352 | 0.200 | Why? | 
| Canada | 1 | 2024 | 417 | 0.200 | Why? | 
| Ventricular Function, Left | 2 | 2016 | 540 | 0.200 | Why? | 
| Problem Solving | 1 | 2022 | 156 | 0.180 | Why? | 
| Hydroxychloroquine | 1 | 2020 | 59 | 0.170 | Why? | 
| Patient Satisfaction | 1 | 2024 | 657 | 0.170 | Why? | 
| Critical Pathways | 1 | 2021 | 89 | 0.170 | Why? | 
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 16 | 0.170 | Why? | 
| Furosemide | 1 | 2020 | 37 | 0.160 | Why? | 
| Physician-Patient Relations | 1 | 2024 | 552 | 0.160 | Why? | 
| Receptors, Atrial Natriuretic Factor | 1 | 2019 | 3 | 0.160 | Why? | 
| Troponin | 1 | 2019 | 51 | 0.160 | Why? | 
| Streptococcus mutans | 1 | 2019 | 8 | 0.160 | Why? | 
| Cryoglobulins | 1 | 2018 | 6 | 0.150 | Why? | 
| Mycoplasma Infections | 1 | 2018 | 15 | 0.150 | Why? | 
| Glomerulonephritis | 1 | 2019 | 47 | 0.150 | Why? | 
| Conservative Treatment | 1 | 2019 | 32 | 0.150 | Why? | 
| Multimorbidity | 1 | 2019 | 47 | 0.150 | Why? | 
| Elasticity Imaging Techniques | 1 | 2019 | 60 | 0.150 | Why? | 
| Rheumatic Diseases | 1 | 2019 | 80 | 0.150 | Why? | 
| Educational Measurement | 1 | 2019 | 280 | 0.130 | Why? | 
| Warfarin | 1 | 2018 | 149 | 0.130 | Why? | 
| Streptococcal Infections | 1 | 2019 | 151 | 0.130 | Why? | 
| Inpatients | 1 | 2021 | 497 | 0.130 | Why? | 
| Middle Aged | 6 | 2021 | 33118 | 0.130 | Why? | 
| Liver Cirrhosis | 1 | 2019 | 316 | 0.130 | Why? | 
| Hepatitis C | 1 | 2019 | 262 | 0.130 | Why? | 
| Cross-Sectional Studies | 2 | 2024 | 5398 | 0.120 | Why? | 
| Fibrinolytic Agents | 1 | 2018 | 271 | 0.120 | Why? | 
| Risk Assessment | 3 | 2021 | 3432 | 0.120 | Why? | 
| Treatment Outcome | 6 | 2022 | 10768 | 0.110 | Why? | 
| Male | 10 | 2024 | 67308 | 0.110 | Why? | 
| Arterio-Arterial Fistula | 1 | 2014 | 4 | 0.110 | Why? | 
| Patient Discharge | 1 | 2021 | 887 | 0.110 | Why? | 
| Sensitivity and Specificity | 1 | 2019 | 1945 | 0.110 | Why? | 
| Coronary Aneurysm | 1 | 2014 | 14 | 0.110 | Why? | 
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 129 | 0.110 | Why? | 
| Coronary Vessel Anomalies | 1 | 2014 | 34 | 0.110 | Why? | 
| Ventricular Remodeling | 1 | 2016 | 262 | 0.110 | Why? | 
| Heart Valve Prosthesis Implantation | 1 | 2016 | 182 | 0.110 | Why? | 
| Incidental Findings | 1 | 2014 | 87 | 0.100 | Why? | 
| Aortic Valve Stenosis | 1 | 2016 | 228 | 0.100 | Why? | 
| Anticoagulants | 1 | 2018 | 662 | 0.100 | Why? | 
| Ventricular Dysfunction, Left | 1 | 2016 | 389 | 0.100 | Why? | 
| Heart Block | 1 | 2012 | 41 | 0.100 | Why? | 
| Cardiac Catheterization | 1 | 2016 | 528 | 0.100 | Why? | 
| Tachycardia, Supraventricular | 1 | 2012 | 45 | 0.100 | Why? | 
| Percutaneous Coronary Intervention | 1 | 2018 | 478 | 0.100 | Why? | 
| Mitral Valve | 1 | 2012 | 89 | 0.100 | Why? | 
| Heart Conduction System | 1 | 2012 | 100 | 0.100 | Why? | 
| Myocardial Infarction | 1 | 2019 | 1044 | 0.090 | Why? | 
| Surveys and Questionnaires | 1 | 2024 | 5730 | 0.090 | Why? | 
| Emergency Service, Hospital | 2 | 2021 | 2033 | 0.090 | Why? | 
| Heart Valve Diseases | 1 | 2012 | 152 | 0.090 | Why? | 
| Follow-Up Studies | 1 | 2019 | 5126 | 0.080 | Why? | 
| Catheter Ablation | 1 | 2012 | 348 | 0.080 | Why? | 
| Aged | 5 | 2020 | 23641 | 0.070 | Why? | 
| Cardiac Surgical Procedures | 1 | 2012 | 531 | 0.070 | Why? | 
| United States | 1 | 2024 | 14595 | 0.070 | Why? | 
| Adult | 5 | 2022 | 37595 | 0.070 | Why? | 
| Female | 7 | 2024 | 72703 | 0.060 | Why? | 
| Kaplan-Meier Estimate | 2 | 2016 | 892 | 0.050 | Why? | 
| Inservice Training | 1 | 2024 | 113 | 0.050 | Why? | 
| Proportional Hazards Models | 2 | 2016 | 1262 | 0.050 | Why? | 
| Time Factors | 3 | 2016 | 6802 | 0.040 | Why? | 
| Treatment Failure | 1 | 2020 | 353 | 0.040 | Why? | 
| Recombinant Fusion Proteins | 1 | 2022 | 664 | 0.040 | Why? | 
| Clinical Protocols | 1 | 2021 | 268 | 0.040 | Why? | 
| Self Report | 1 | 2024 | 827 | 0.040 | Why? | 
| Aged, 80 and over | 3 | 2016 | 7552 | 0.040 | Why? | 
| Vibration | 1 | 2019 | 71 | 0.040 | Why? | 
| Retrospective Studies | 4 | 2019 | 15514 | 0.040 | Why? | 
| Severity of Illness Index | 2 | 2016 | 2833 | 0.040 | Why? | 
| Inflammation Mediators | 1 | 2021 | 514 | 0.040 | Why? | 
| Double-Blind Method | 1 | 2022 | 1980 | 0.030 | Why? | 
| Cold Temperature | 1 | 2018 | 177 | 0.030 | Why? | 
| Risk Factors | 3 | 2016 | 10313 | 0.030 | Why? | 
| Fibrosis | 1 | 2019 | 552 | 0.030 | Why? | 
| Comorbidity | 1 | 2021 | 1611 | 0.030 | Why? | 
| Diastole | 1 | 2016 | 150 | 0.030 | Why? | 
| Evidence-Based Medicine | 1 | 2019 | 744 | 0.030 | Why? | 
| Patient Readmission | 1 | 2021 | 693 | 0.030 | Why? | 
| Heart Valve Prosthesis | 1 | 2016 | 116 | 0.030 | Why? | 
| Age Factors | 1 | 2021 | 3290 | 0.030 | Why? | 
| Voltage-Sensitive Dye Imaging | 1 | 2012 | 4 | 0.030 | Why? | 
| Stroke Volume | 1 | 2016 | 611 | 0.030 | Why? | 
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 82 | 0.020 | Why? | 
| Recovery of Function | 1 | 2016 | 657 | 0.020 | Why? | 
| Coronary Angiography | 1 | 2014 | 314 | 0.020 | Why? | 
| Algorithms | 1 | 2019 | 1695 | 0.020 | Why? | 
| Reproducibility of Results | 1 | 2019 | 3282 | 0.020 | Why? | 
| Chi-Square Distribution | 1 | 2012 | 533 | 0.020 | Why? | 
| Databases, Factual | 1 | 2016 | 1345 | 0.020 | Why? | 
| Hospitalization | 1 | 2019 | 2183 | 0.020 | Why? | 
| Recurrence | 1 | 2012 | 1058 | 0.020 | Why? | 
| Electrocardiography | 1 | 2012 | 632 | 0.020 | Why? | 
| Action Potentials | 1 | 2012 | 502 | 0.020 | Why? | 
| Predictive Value of Tests | 1 | 2014 | 2030 | 0.020 | Why? | 
| Biomarkers | 1 | 2019 | 4148 | 0.020 | Why? | 
| Tomography, X-Ray Computed | 1 | 2014 | 2670 | 0.010 | Why? | 
| Magnetic Resonance Imaging | 1 | 2014 | 3710 | 0.010 | Why? | 
| Adolescent | 1 | 2019 | 21402 | 0.010 | Why? |